Pharmaceutical preparations company · L3 · FY ends Dec · Revenue $19M · -38.88% margin · $275K FCF
The business is unprofitable at the operating level (-38.88% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 68.0% YoY with margins expanding 65.2pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$19M
▲ +68.0% YoY
Net Income (TTM)
-$6M
▲ +42.1% YoY
Op. Margin
-38.88%
▲ +65.2pp YoY
ROIC
-22.07%
▲ +4.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$275K
▲ +102.0% YoY
Op. Cash Flow (TTM)
$322K
▲ +102.3% YoY
Net Debt
-$23M
Net Cash Position
Cash & Equiv.
$24M
5Y CAGR: +17.2%
Continue Research